Power to the Patients copertina

Power to the Patients

Power to the Patients

Di: Brandon Li
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com315762 Scienza Scienze biologiche
Episodi
  • Why Enveda Teaches AI to Read Nature's Chemistry

    Why Enveda Teaches AI to Read Nature's Chemistry
    Sep 9 2026
    Isn’t it crazy to think that half of FDA-approved small molecule drugs have roots in nature? But José Trevejo, Chief Medical Officer at Enveda, says the opportunity now is not to romanticize that history, but to make it usable at modern speed. In this episode of Power to the Patients, Brandon Li speaks with José about AI-assisted drug discovery, mass spectrometry, ENV-294 and why the real bottleneck in biotech may no longer be finding molecules. It may be scaling the trials to test them. By combining ancient healing stories with high-throughput technology, researchers now identify these candidates in hours rather than years. This clinical acceleration is rewriting the early-stage discovery playbook.
    Mostra di più Mostra meno
    41 min
  • Reversing Chemo failure in ovarian cancer with Thomas Zindrick

    Reversing Chemo failure in ovarian cancer with Thomas Zindrick
    Aug 19 2026
    Platinum chemotherapy is the backbone of ovarian cancer treatment. But for far too many patients, it eventually stops working. In this episode of Power to the Patients, Brandon Li sits down with Thomas Zindrick, CEO and President of Genelux Corporation, to discuss Olvi-Vec, platinum resensitization, and why oncolytic virus therapy could give clinicians a new way to work with existing cancer treatments. Platinum resistance is one of the hardest questions to solve in clinical oncology, but some answers are beginning to emerge.
    Mostra di più Mostra meno
    38 min
  • The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently

    The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently
    Jul 23 2026
    Most people still think gout is a lifestyle condition caused primarily by diet. But this belief is a big reason patients have been underserved for decades. In this episode of Power to the Patients, Brandon Li sits down with James Mackay, CEO and co-founder of Crystalys Therapeutics, to explore what gout patients really need. They unpack what went wrong with Zurampic, why Dotinurad’s profile gives Crystalys Therapeutics a reason to come back to gout and how better trial design could finally move the field beyond old assumptions. For decades, gout has often been framed as a disease caused by lifestyle choices. This episode reframes the conversation entirely.
    Mostra di più Mostra meno
    36 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione